AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-93686997/trial-shows-astrazeneca-thrombosis.html" title="Facts and information about Trial shows AstraZeneca's thrombosis drug Exanta to be superior to rival.(Brief Article)">Trial shows AstraZeneca's thrombosis drug Exanta to be superior to rival.(Brief Article)</a>
Close
Set up an RSS feed that alerts you when new articles from M2 Europharma are available.
Frequently asked questions about RSS feeds
Trial shows AstraZeneca's thrombosis drug Exanta to be superior to rival.(Brief Article)
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
Anglo-Swedish drug group AstraZeneca Plc has claimed that a trial of its thrombosis drug Exanta found it to be superior to Aventis SA's Lovenox.
According to AstraZeneca, the EXPRESS phase III clinical trial with Exanta (oral ximelagatran and its active form, melagatran) that showed the drug's superior efficacy compared to Lovenox (enoxaparin) in preventing blood clotting after major hip and knee replacement …
Related articles from newspapers, magazines, journals, and more
